Alaska Department of Revenue Reduces Holdings in Bruker Corporation by 0.5%
July 4, 2023
🌥️Trending News
The Alaska Department of Revenue recently revealed that during the first quarter of 2021, it reduced its holdings in Bruker Corporation ($NASDAQ:BRKR) by 0.5%. Bruker Corporation is a leading manufacturer of scientific instruments, analytical and diagnostic solutions for life sciences. Their products are used in a variety of industries, including pharmaceuticals, biotechnology, medical research, and more. Bruker’s products have been used to advance a variety of scientific research, making them an important contributor to the advancement and progress of many industries.
Over the past year, the company’s stock has grown significantly, making it a great choice for investors. With the State of Alaska Department of Revenue reducing its holdings in the company’s stock by 0.5%, many investors may be looking for an opportunity to capitalize on this lowering of holdings.
Earnings
This is based on Bruker Corporation‘s earning report for FY2023 Q1 as of March 31 2021. According to the report, Bruker Corporation earned 554.7M USD in total revenue and 56.7M USD in net income. Compared to the same period last year, there was a 6.8% decrease in total revenue and an 8.0% decrease in net income. Although current figures are lower than the previous year, Bruker Corporation’s total revenue has grown from 554.7M USD to 685.3M USD over the last 3 years.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Bruker Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 2.62k | 311.5 | 12.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bruker Corporation. More…
| Operations | Investing | Financing |
| 284.1 | -258 | -228.6 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bruker Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.76k | 2.55k | 7.58 |
Key Ratios Snapshot
Some of the financial key ratios for Bruker Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.8% | 21.4% | 17.4% |
| FCF Margin | ROE | ROA |
| 5.7% | 24.6% | 7.6% |
Analysis
As a GoodWhale analyst, I recently conducted an analysis of BRUKER CORPORATION‘s financials. The results were very promising; according to the Star Chart, BRUKER CORPORATION has an impressive health score of 9/10 due to its strong cashflows and debt situation. BRUKER CORPORATION has strong assets, dividend, growth, and profitability, and is classified as a ‘gorilla’, meaning that the company has achieved stable and high revenue or earnings growth due to its strong competitive advantage. Given its impressive financials and strong competitive advantage, BRUKER CORPORATION could be an attractive investment opportunity for various types of investors. For example, value investors may be attracted to the company’s strong dividend and debt-paying capabilities, while growth investors may be drawn to the company’s potential for sustained long-term earnings growth. BRUKER CORPORATION may also be of interest to active traders due to its strong performance in recent years. In short, BRUKER CORPORATION has the potential to be a great investment opportunity for a range of investors. More…
Peers
Its products are used in a variety of applications, including drug discovery, food and environmental testing, and materials science research. The company’s main competitors are Tecan Group AG, Stevanato Group SPA, and Cerus Corporation.
– Tecan Group AG ($LTS:0QLN)
Tecan Group AG is a leading provider of laboratory instruments and solutions. The company has a market cap of 4.56B as of 2022 and a Return on Equity of 6.13%. Tecan provides a wide range of products and services for the life science research, diagnostics and pharmaceutical sectors. The company offers a broad range of solutions for drug discovery, genomics, diagnostics and forensics. Tecan also provides contract research services to the pharmaceutical industry.
– Stevanato Group SPA ($NYSE:STVN)
Stevanato Group SPA is a company that manufactures and sells pharmaceuticals and medical devices. The company has a market cap of 4.89B as of 2022 and a return on equity of 11.0%. The company’s products are sold in over 100 countries and it has a presence in Europe, North America, and Asia.
– Cerus Corp ($NASDAQ:CERS)
Cerus Corp is a medical technology company that specializes in blood safety. The company’s primary product is the Intercept Blood System, which is designed to inactivate viruses, bacteria, parasites, and other potentially harmful agents in donated blood. Cerus Corp’s market cap as of 2022 is 625.13M, and its ROE is -28.3%. The company has been facing some financial difficulties in recent years, but continues to invest in research and development in order to bring new products to market.
Summary
This suggests that investors are confident in Bruker’s future prospects and are willing to hold onto their investments. Analysts have recommended investing in Bruker due to its strong balance sheet, innovative product pipeline, and strong customer base. Additionally, Bruker has also strengthened its research and development capabilities, allowing it to bring new products to market quickly. It is expected that this trend will continue as the company continues to grow and expand its reach globally.
Related Posts
Recent Posts
